B. Callendret

发表

Combination Ad26.RSV.preF/RSV preF protein vaccine induces superior humoral, cellular, and protective immunity compared with individual vaccine components in preclinical models

H. Schuitemaker, L. van der Fits, F. Cox, 2022, bioRxiv.

Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein

N. Escriou, F. Tangy, P. Marianneau, 2014, Virology.

Transmission of Clonal Hepatitis C Virus Genomes Reveals the Dominant but Transitory Role of CD8+ T Cells in Early Viral Evolution

A. Hughes, R. Purcell, J. Bukh, 2011, Journal of Virology.

Impact of prophylactic vaccination strategies on Ebola virus transmission: A modeling analysis

R. Potluri, A. Kumar, Benoît Callendret, 2020, PloS one.

Heterologous viral RNA export elements improve expression of severe acute respiratory syndrome (SARS) coronavirus spike protein and protective efficacy of DNA vaccines against SARS

N. Escriou, J. Betton, H. Contamin, 2007, Virology.

Stable Cytotoxic T Cell Escape Mutation in Hepatitis C Virus Is Linked to Maintenance of Viral Fitness

C. Rice, C. Walker, A. Grakoui, 2008, PLoS pathogens.

A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks

Benoît Callendret, M. Douoguih, G. Shukarev, 2016, Human vaccines & immunotherapeutics.

Anti-Severe Acute Respiratory Syndrome Coronavirus Spike Antibodies Trigger Infection of Human Immune Cells via a pH- and Cysteine Protease-Independent FcγR Pathway

J. Peiris, R. Bruzzone, B. Nal, 2011, Journal of Virology.

Novel Infectious cDNA Clones of Hepatitis C Virus Genotype 3a (Strain S52) and 4a (Strain ED43): Genetic Analyses and In Vivo Pathogenesis Studies

R. Purcell, J. Bukh, C. Walker, 2010, Journal of Virology.

Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries

J. Nguyen-Van-Tam, E. Martin, R. Fleischhackl, 2022, European Respiratory Review.

Dominance of the CD4+ T helper cell response during acute resolving hepatitis A virus infection

A. Perelson, S. Lemon, Yan Zhou, 2012, The Journal of experimental medicine.

Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study

V. Bockstal, Benoît Callendret, Auguste Gaddah, 2020, The Journal of infectious diseases.

Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate

H. Schuitemaker, Yvonne Wollmann, R. Roozendaal, 2020, NPJ vaccines.

Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans

H. Schuitemaker, Yvonne Wollmann, R. Roozendaal, 2023, Frontiers in immunology.

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola

H. Schuitemaker, D. Heerwegh, R. Roozendaal, 2022, npj Vaccines.

Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels

H. Schuitemaker, N. Sullivan, R. Roozendaal, 2022, Vaccines.

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial

S. Lees, D. Watson-Jones, B. Lowe, 2021, The Lancet. Infectious diseases.

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

S. Lees, D. Watson-Jones, B. Lowe, 2021, The Lancet. Infectious diseases.

A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates

H. Schuitemaker, J. Custers, C. Mire, 2018, PloS one.

Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.

H. Schuitemaker, N. Frahm, M. McElrath, 2016, JAMA.

Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine with an Adenovirus 26 Vector Encoding Pre-Fusion F (Ad26.RSV.preF) in adults 60 years and older.

H. Schuitemaker, J. Langedijk, J. Sadoff, 2020, The Journal of infectious diseases.

First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study

M. McElrath, S. D. De Rosa, M. Pau, 2022, PloS one.

Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate

H. Schuitemaker, Yvonne Wollmann, R. Roozendaal, 2020, npj Vaccines.

Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adults

C. Truyers, M. Douoguih, N. Goldstein, 2016 .

Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical models.

H. Schuitemaker, L. van der Fits, J. Langedijk, 2021, Vaccine.

Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults.

H. Schuitemaker, J. Sadoff, W. Haazen, 2020, The Journal of infectious diseases.

Adenoviral Type 35 and 26 Vectors with a Bidirectional Expression Cassette in the E1 Region Show an Improved Genetic Stability Profile and Potent Transgene-Specific Immune Response.

H. Schuitemaker, Mark Vermeulen, J. Custers, 2017, Human gene therapy.

Persistent hepatitis C viral replication despite priming of functional CD8+ T cells by combined therapy with a vaccine and a direct‐acting antiviral

A. Folgori, R. Cortese, A. Nicosia, 2015, Hepatology.

Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1)

G. Freeman, C. Rice, R. Ahmed, 2013, Proceedings of the National Academy of Sciences.

Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults.

A. Falsey, J. Sadoff, J. Menten, 2023, The New England journal of medicine.

T‐cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon‐free antiviral regimen in a chimpanzee

A. Folgori, R. Cortese, A. Nicosia, 2014, Hepatology.

Selection‐driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection

A. Hughes, C. Walker, D. Hasselschwert, 2010, Hepatology.

Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV-Seropositive Children 12–24 Months

M. Snape, W. Haazen, S. Faust, 2022, The Journal of infectious diseases.

Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study

Rob Lambkin-Williams, A. Gilbert, H. Schuitemaker, 2021, The Journal of infectious diseases.

Antibody effector functions are associated with protection from respiratory syncytial virus

D. Lauffenburger, G. Alter, L. van der Fits, 2022, Cell.